Directions of therapeutic goals should aim at monitoring and decreasing over-expression of the metabolites contributing to coagulation diseases and increasing the counterattack of PON1 (Paraoxonase 1) to prevent cardiovascular morbidity.50 Other cellular processes plagued by T2DM patients include compromised wound healing, which is regulated by TNF and LEP metabolites; regulating their over-expression could resolve wound healing complications.51 The gene discussed is TNF; the disease is type 2 diabetes mellitus.